| Balance Sheets | 2025-09-30 | 2025-06-30 | ||
|---|---|---|---|---|
| Cash and cash equivalents | 74,577 | 71,143 | ||
| Marketable securities | 129,445 | 184,590 | ||
| Accounts and other receivables, net | 1,045 | 625 | ||
| Prepaid expenses and other current assets | 8,929 | 6,215 | ||
| Inventory | 2,110 | 2,678 | ||
| Total current assets | 216,106 | 265,251 | ||
| Property and equipment, net | 8,861 | 8,762 | ||
| Operating lease right-of-use assets | 20,660 | 21,089 | ||
| Restricted cash | 150 | 150 | ||
| Other assets | 5,918 | 5,895 | ||
| Total assets | 251,695 | 301,147 | ||
| Deferred revenue | - | 0 | ||
| Accounts payable | 10,076 | 19,685 | ||
| Accrued expenses | 17,943 | 11,478 | ||
| Other current liabilities | 2,075 | 2,012 | ||
| Total current liabilities | 30,094 | 33,175 | ||
| Deferred revenue - noncurrent | 0 | 0 | ||
| Operating lease liabilities - noncurrent | 21,301 | 21,815 | ||
| Other noncurrent liabilities | 118 | 148 | ||
| Total liabilities | 51,513 | 55,138 | ||
| Preferred stock, .001 par value, 5,000,000 shares authorized, no shares issued and outstanding | 0 | 0 | ||
| Common stock, .001 par value, 300,000,000 shares authorized at september 30, 2025 and december 31, 2024 69,569,813 and 68,266,005 shares issued and outstanding at september 30, 2025 and december 31, 2024, respectively | 70 | 69 | ||
| Additional paid-in capital | 1,236,562 | 1,222,745 | ||
| Accumulated deficit | -1,037,369 | -977,637 | ||
| Accumulated other comprehensive income (loss) | 919 | 832 | ||
| Total stockholders' equity | 200,182 | 246,009 | ||
| Total liabilities and stockholders' equity | 251,695 | 301,147 | ||
EyePoint Pharmaceuticals, Inc. (EYPT)
EyePoint Pharmaceuticals, Inc. (EYPT)